| 证券代码：300677 | 证券简称：英科医疗 | 公告编号：2025-101 | | --- | --- | --- | | 债券代码：123029 | 债券简称：英科转债 | | 英科医疗科技股份有限公司 关于英科转债即将到期暨赎回的第三次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 经中国证券监督管理委员会"证监许可[2019]1183 号"文核准， 公司于 2019 年 8 月 16 日公开发行了 470 万张可转债，每张面值 100 元，发行总额 4.70 亿元。 1、"英科转债"到期日：2025 年 8 月 15 日； 2、"英科转债"到期兑付价格：128 元人民币/张（含最后一期 利息）； 3、"英科转债"最后转股日：2025 年 8 月 15 日； 4、"英科转债"最后交易日为 2021 年 6 月 28 日，已于 2021 年 6 月 29 日停止交易。在停止交易后、转股期结束前（即 2021 年 6 月 29 日至 2025 年 8 月 15 日），"英科转债"持有人仍可以依据约定 的条件，将"英科转债"转换为 ...

| 证券代码：300677 | 证券简称：英科医疗 | 公告编号：2025-100 | | --- | --- | --- | | 债券代码：123029 | 债券简称：英科转债 | | 英科医疗科技股份有限公司 关于英科转债即将到期暨赎回的第二次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、"英科转债"到期日：2025 年 8 月 15 日； 2、"英科转债"到期兑付价格：128 元人民币/张（含最后一期 利息）； 3、"英科转债"最后转股日：2025 年 8 月 15 日； 4、"英科转债"最后交易日为 2021 年 6 月 28 日，已于 2021 年 6 月 29 日停止交易。在停止交易后、转股期结束前（即 2021 年 6 月 29 日至 2025 年 8 月 15 日），"英科转债"持有人仍可以依据约定 的条件，将"英科转债"转换为公司股票，目前转股价格为人民币 3.26 元/股； 5、截至 2025 年 8 月 15 日收市后仍未转股的"英科转债"将被 强制赎回；本次赎回完成后，"英科转债"将在深圳证券交易所摘牌。 ...

Trading Information Summary - On July 11, 2025, the stock price of Yingke Medical (300677) closed at 26.78 yuan, down 0.37%, with a turnover rate of 3.63% and a trading volume of 168,700 shares, amounting to a total transaction value of 455 million yuan [1] - On the same day, the net inflow of main funds was 25.4 million yuan, while retail investors experienced a net outflow of 21.1 million yuan [3] Company Announcements Summary - Yingke Medical adjusted the conversion price of its convertible bonds from 3.39 yuan/share to 3.26 yuan/share, effective from July 11, 2025 [1][3] - The company completed the repurchase and cancellation of 4,504,300 shares, accounting for 0.6969% of the total share capital, reducing the total share capital from 646,326,180 shares to 641,821,880 shares [2][3] - Following the share cancellation, the shareholding ratio of the controlling shareholder, Liu Fangyi, increased from 35.85% to 36.10% [2] - The "Yingke Convertible Bonds" will mature on August 15, 2025, with a redemption price of 128 yuan per bond (including the last interest payment), and the last conversion date is also August 15, 2025 [2][3]

Group 1 - The core point of the announcement is that Yingke Medical Technology Co., Ltd. is reminding holders of its convertible bonds ("Yingke Convertible Bonds") about the upcoming expiration and conversion options [1][2][3] - The "Yingke Convertible Bonds" were issued on August 16, 2019, with a total amount of 470 million yuan, and are currently trading on the Shenzhen Stock Exchange under the code "123029" [1][2] - The conversion price for the bonds is set at 3.26 yuan per share, allowing bondholders to convert their bonds into company stock during the conversion period [1][2] Group 2 - The bonds will be redeemed at 128% of their face value, which amounts to 128 yuan per bond, including the last interest payment, within five trading days after the maturity date of August 15, 2025 [2][3] - The trading of "Yingke Convertible Bonds" was suspended on June 29, 2021, and will not resume before the end of the conversion period [2] - The company will publish announcements regarding the bond's maturity and delisting on the designated information disclosure website [3]

| 证券代码：300677 | 证券简称：英科医疗 | 公告编号：2025-099 | | --- | --- | --- | | 债券代码：123029 | 债券简称：英科转债 | | 英科医疗科技股份有限公司 关于英科转债即将到期暨赎回的第一次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、"英科转债"到期日：2025 年 8 月 15 日； 2、"英科转债"到期兑付价格：128 元人民币/张（含最后一期 利息）； 3、"英科转债"最后转股日：2025 年 8 月 15 日； 4、"英科转债"最后交易日为 2021 年 6 月 28 日，已于 2021 年 6 月 29 日停止交易。在停止交易后、转股期结束前（即 2021 年 6 月 29 日至 2025 年 8 月 15 日），"英科转债"持有人仍可以依据约定 的条件，将"英科转债"转换为公司股票，目前转股价格为人民币 3.26 元/股； 5、截至 2025 年 8 月 15 日收市后仍未转股的"英科转债"将被 强制赎回；本次赎回完成后，"英科转债"将在深圳证券交易所摘牌。 ...

Summary of Key Points Core Viewpoint The announcement details the completion of a share buyback and cancellation by Yingke Medical Technology Co., Ltd., which has resulted in a change in the shareholding structure of the company, particularly affecting the stake of the controlling shareholder. Group 1: Share Buyback Overview - The company repurchased 4,504,300 shares, which accounted for approximately 0.6969% of the total share capital before the cancellation [1][2]. - The buyback was conducted using a budget of between RMB 100 million and RMB 200 million, with a maximum repurchase price of RMB 33.03 per share [1]. - The buyback was intended for employee stock ownership plans and/or equity incentives, but the purpose was later changed to reduce registered capital [1][2]. Group 2: Completion of Share Cancellation - The cancellation of the repurchased shares was confirmed to be completed on July 10, 2025, resulting in a reduction of the total share capital from 646,326,180 shares to 641,821,880 shares [2]. - The shareholding structure post-cancellation shows that the proportion of restricted shares increased slightly, while the proportion of unrestricted shares decreased [2]. - The controlling shareholder, Liu Fangyi, increased his shareholding from 35.85% to 36.10% following the cancellation [1][2]. Group 3: Impact on Company Structure - The share buyback and cancellation will not materially affect the company's financial status or operational results, nor will it harm the interests of minority investors [2]. - The company will proceed with necessary legal registrations and amendments to its articles of association following the completion of the share cancellation [3].

证券代码：300677 证券简称：英科医疗 公告编号：2025-097 2、经中国证券登记结算有限责任公司深圳分公司确认，公司本 次回购股份注销事宜已于 2025 年 7 月 10 日办理完成。 3、因注销回购股份导致公司总股本发生变动，公司控股股东、 实际控制人刘方毅先生持有公司股份比例由 35.85%增加至 36.10%。 一、回购股份情况概述 1、公司于 2023 年 7 月 13 日召开第三届董事会第十五次会议和 第三届监事会第十四次会议，审议通过了《关于公司回购股份方案的 议案》，同意公司使用不低于人民币 10,000 万元（含本数）且不超过 人民币 20,000 万元（含本数）的自有资金，以集中竞价交易的方式回 购部分公司股份（人民币普通股（A 股）股票），用于实施员工持股 计划及/或股权激励。回购价格不超过人民币 33.03 元/股（含本数）， 回购股份的数量和金额以回购期限届满时实际回购的股份数量和金 额为准。回购股份的实施期限为自公司第三届董事会第十五次会议审 议通过本次回购股份方案之日起不超过 12 个月。具体内容详见公司 分别于 2023 年 7 月 13 日、2023 年 7 月 17 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： | | | 债券代码：123029 债券简称：英科转债 调整前转股价格：人民币 3.39 元/股 调整后转股价格：人民币 3.26 元/股 转股价格调整生效日期：2025 年 7 月 11 日 | 证券简称：英科医疗 | 公告编号：2025-098 | | --- | --- | | 债券简称：英科转债 | | | 证券代码：300677 债券代码：123029 | | 英科医疗科技股份有限公司 关于部分回购股份注销调整"英科转债"转股价格 的公告 本次调整可转债转股价格不涉及暂停转股事项 一、关于可转换公司债券转股价格调整的相关规定 英科医疗科技股份有限公司（以下简称"公司"）公开发行了 470 万张可转换公司债券（债券简称：英科转债，债券代码：123029）并 于 2019 年 9 月 10 日上市。根据《山东英科医疗用品股份有限公司创 业板公开发行可转换公司债券募集说明书》及中国证券监督管理委员 会关于可转换公司债券发行的有关规定，当公司发生派送股票股利、 转增股本、增发新股（不包括因本次发行的 ...

Core Viewpoint - The company, Yingke Medical (300677), has announced the cancellation of 4.5043 million shares repurchased, which accounts for 0.6969% of the total share capital before the cancellation, amounting to 646 million shares [1] Summary by Relevant Sections - Share Cancellation Details - The total number of shares canceled is 4.5043 million [1] - The total share capital will decrease from 646 million shares to 642 million shares after the cancellation [1] - Impact on Shareholding Structure - Following the cancellation, the shareholding percentage of the controlling shareholder and actual controller, Mr. Liu Fangyi, will increase from 35.85% to 36.10% [1] - Financial and Operational Impact - The share cancellation will not have a substantial impact on the company's financial status or operational results [1] - There will be no change in the controlling shareholder or actual controller, and the company's equity distribution remains compliant with listing requirements [1]

Core Insights - The core viewpoint of the article emphasizes the significant advancements made by the company in its environmental, social, and governance (ESG) practices, particularly through innovation and green initiatives. Group 1: Innovation and R&D Investment - In 2024, the company increased its R&D investment to 398 million yuan, a 40% increase from 284 million yuan in 2023 [1][3] - The number of R&D personnel rose from 972 in 2023 to over 1200, accounting for more than 10% of the total workforce [3] - The company launched 55 new products in the past year, a 197% increase, covering three core areas: medical consumables, health care devices, and medical care [4] Group 2: Environmental Impact and Green Initiatives - The carbon emissions per glove decreased to 20.41 grams, a reduction of 20.70% compared to the previous year [4] - Water consumption per glove was reduced to 0.21 liters, down 11.02% from the previous year [4] - The company is investing in clean energy, with wind power infrastructure expected to be operational by 2025 [6] Group 3: Social Responsibility and Community Engagement - The company donated over 300 wheelchairs to hospitals and communities, contributing to the equitable distribution of medical resources [8][10] - It has committed over 75.82 million yuan to social welfare since implementing its corporate social responsibility initiatives [10] - The company supports employee development with a 100% training coverage rate and an annual investment of 1.4914 million yuan in skills enhancement [8] Group 4: Corporate Governance and Supply Chain Management - The company has optimized its governance structure, with all seven board members possessing extensive industry knowledge [12] - It is building a sustainable supply chain ecosystem through strict supplier evaluation standards and capacity-building initiatives [12][15] - The company aims to reduce carbon emissions per glove by 25% by 2030 and achieve carbon neutrality in its operations by 2025 [15]